Furthermore, YTHDF2 is aberrantly elevated in relapsed AML patients, where it binds to m6A-modified pre-miR-126, recruits AGO2, and promotes its maturation into the oncogenic miRNA miR-126, thereby enhancing leukemic proliferation and leukemogenesis (50). The gene discussed is YTHDF2; the disease is acute myeloid leukemia.